| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/10/2007 | US20070105903 Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
| 05/10/2007 | US20070105902 4-Phenyl piperdine sulfonyl glycine transporter inhibitors |
| 05/10/2007 | US20070105901 Novel piperidine derivative |
| 05/10/2007 | US20070105900 Pharmaceutical compounds |
| 05/10/2007 | US20070105899 Benzene compounds |
| 05/10/2007 | US20070105898 Process for the production of cilostazol |
| 05/10/2007 | US20070105897 Novel quinuclidine derivatives and medicinal compositions containing the same |
| 05/10/2007 | US20070105896 3-Imidazol-1-yl-1-azabicyclo[2.2.2]octane; agonist, partial agonist, or antagonist of the alpha 7 nicotinic acetylcholine receptor; antidepressant, anxiolytic agent, cognition activator, neuroprotectant; radiolabel |
| 05/10/2007 | US20070105895 3-Substituted alkyl-8-methyl-8-aza-bicyclo[3.2.1]octanes, e.g., 3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propionitrile, COPD, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis |
| 05/10/2007 | US20070105894 Combination of at least two compounds selected from an AT1-receptorantagonist or an ACE inhibitor or a HMG-Co-A reductase inhibitor |
| 05/10/2007 | US20070105893 e.g. 2-[(4-Ethoxyphenyl)methyl]-1-(3-methylbutyl)-N,N-bis(2,2,2-trifluoroethyl)-1H-benzimidazole-5-carboxamide; agonists at cannabinoid 2 receptor; analgesic agent, anticarcinogenic agent, neurodegenerative diseases; multiple sclerosis, Parkinson's disease, Huntington's chorea or Alzheimer's disease. |
| 05/10/2007 | US20070105892 Amidino compounds as cysteine protease inhibitors |
| 05/10/2007 | US20070105891 Thiazole[4,5-C]pyridine derivatives |
| 05/10/2007 | US20070105890 Novel condensed imidazole derivative |
| 05/10/2007 | US20070105889 Administering (S)-1-(2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)-2-propylamine; serotonin receptor antagonists (5HT/5HT2C) for therapy of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea |
| 05/10/2007 | US20070105888 Metabolically resistant 41-[13C]methoxyl rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (41-[13C]methoxyl CCI-779); study pharmacokinetics; Rapamycin 31-O-trimethyl silyl ether, 42-ester with 2,2,5-trimethyl[1,3-dioxane]-5-carboxylic acid; treat cancers |
| 05/10/2007 | US20070105887 Antineoplastic combinations of temsirolimus and sunitinib malate |
| 05/10/2007 | US20070105886 Steroidal compounds for inhibiting steroid sulphatase |
| 05/10/2007 | US20070105885 Novel crystalline polymorphic form of a camptothecin analogue |
| 05/10/2007 | US20070105884 Opiate analogs selective for the delta-opioid receptor |
| 05/10/2007 | US20070105883 Novel physiologically active substances pf127oa, b and c substances |
| 05/10/2007 | US20070105882 Polymorphic forms of a known antihyperlipemic agent |
| 05/10/2007 | US20070105881 For improving perception, concentration, learning or memory; 2-(Cyclopentylmethyl)-4-[(fluorophenyl)amino]6-oxo-1,6-dihydro-5-pyrimidinecarbonitrile; amination of methyl 2-cyano propenoate derivatives, cyclization using amidinehydrochloride derivatives |
| 05/10/2007 | US20070105880 Process for the preparation of alfuzosin |
| 05/10/2007 | US20070105879 Ready-for-use injectable solution of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amine-1h-purin-6(9h)-one, sterile, stable; closed system for packing the solution, process for eliminating alkaline residuals of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amine-1h-purin-6 (9h)-one crystals; pharmaceutical presentation as a closed system ready-for-use; uses and methods |
| 05/10/2007 | US20070105878 Purine formulations and methods for managing disorders |
| 05/10/2007 | US20070105877 Pyrazolopyrimidines |
| 05/10/2007 | US20070105876 6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolepyrimidines |
| 05/10/2007 | US20070105874 Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors |
| 05/10/2007 | US20070105872 N-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methylisoxazole-4-carboxamide; N-[6-amino-5-(2,3-dichloro-5-methoxyphenyl)pyrazin-2-yl]-1-methyl-1H-pyrazole-5-carboxamide |
| 05/10/2007 | US20070105871 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders |
| 05/10/2007 | US20070105870 Piperazine derivatives which exhibit activity as serotonin and noradrenaline re-uptake inhibitors |
| 05/10/2007 | US20070105869 Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| 05/10/2007 | US20070105868 3-(2-{5-methyl-2-[4-(trifluoromethyl)piperidin-1-yl]-1,3-thiazol-4-yl}ethoxy)phenyl]acetic acid,peroxime proliferator-activated receptor antagonists; side effect reduction; very low toxicity, especially hepatotoxicity; metabolic disorders; antidiabetic agents; anticholesterol agents; antilipemic agents |
| 05/10/2007 | US20070105867 Oral administration of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof |
| 05/10/2007 | US20070105866 5-lipoxygenase-activating protein (flap) inhibitors |
| 05/10/2007 | US20070105865 Substituted bicyclic quinazolin-4-ylamine derivatives |
| 05/10/2007 | US20070105864 Methods for inhibiting protein kinases |
| 05/10/2007 | US20070105863 e.g. 1-(8-(3-hydroxyphenyl)-7,8-dimethyl-hexahydro-1H-pyrido[1,2- alpha ]pyrazin-2(6H)-yl)-2-phenylethanone; analgesics; gastrointestinal dysfunction, post-surgical recovery; side effect reduction |
| 05/10/2007 | US20070105862 Heat-shock protein binders |
| 05/10/2007 | US20070105861 Novel vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations |
| 05/10/2007 | US20070105860 Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors |
| 05/10/2007 | US20070105859 4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors |
| 05/10/2007 | US20070105858 Retinoic acid mimetic anilides |
| 05/10/2007 | US20070105857 Process for Making Heteroaryl Amine Intermediate Compounds |
| 05/10/2007 | US20070105856 6-benzyl-3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-2,6-dihydropyrazolo[3,4-c]pyridin-7-one; eating and psychological disorders; obesity, alcoholism |
| 05/10/2007 | US20070105855 Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| 05/10/2007 | US20070105854 Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| 05/10/2007 | US20070105853 2-'4-(Hydroxymethyl-phenylamino)-piperidine-1-yl!-n-(9h-carbazol-3-yl) - acetamine derivatives and related compounds as neuropeptide y5 (npy5) ligands for the treatment of obesity |
| 05/10/2007 | US20070105852 Thiophene and furan compounds |
| 05/10/2007 | US20070105851 Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis |
| 05/10/2007 | US20070105850 2,4-diChloro-N-(4-cyclopropylmethanesulfonyl-1-cyclopropylmethylcyclohexyl-methyl) benzamide; glutamatergic neurotransmission dysfunction and diseases; dementia; antidepressants; learning enhancement; cognition activators; attention deficit disorders; autism; eating disorders; anxiolytic agents |
| 05/10/2007 | US20070105849 Rifamycin analogs and uses thereof |
| 05/10/2007 | US20070105848 Methylene Blue Therapy of Parasitic Infections |
| 05/10/2007 | US20070105847 1,3-Dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes |
| 05/10/2007 | US20070105846 Phenylene derivative having tetrazole ring or thiazolidinedione ring |
| 05/10/2007 | US20070105845 Quinolone derivatives |
| 05/10/2007 | US20070105844 Therapeutic compositions and methods |
| 05/10/2007 | US20070105843 Combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist |
| 05/10/2007 | US20070105842 purinergic receptor inhibitors; 5-[2-chloro-3-(trifluoromethyl)phenyl]-1-[2,3-dihydro-1H-inden-1-yl]-1H-1,2,4-triazole; [4-(2,3-Dichloro-phenyl)-4H-[1,2,4]triazol-3-yl]-(2-pyrrolidin-1-yl-pyridin-3-ylmethyl)-amine |
| 05/10/2007 | US20070105841 Such as 1-(1-{2-Hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperidin-4-yl)-1,3-dihydro-benzoimidazol-2-one; cathepsin inhibitors |
| 05/10/2007 | US20070105840 Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
| 05/10/2007 | US20070105839 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
| 05/10/2007 | US20070105838 Bicyclic Benzamide Compoundssa as Histamine H3 Receptor Ligand Useful in the Treatment of Neurological Diseases |
| 05/10/2007 | US20070105837 Novel derivatives of 4a,5,9,10,11,12-hexahydrobenzofuro[3a,3,2][2]-benzazepine, method for the production thereof and use thereof in the production of medicaments |
| 05/10/2007 | US20070105836 Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| 05/10/2007 | US20070105835 Compositions and methods for modulating poly(ADP-ribose) polymerase activity |
| 05/10/2007 | US20070105834 histamine H3 receptor modulators; obesity, diabetes and central nervous system diseases such as vigilance and sleep disorders; e.g. (+)-2-(cyclohexylmethyl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl] -1,2,3 ,4-tetrahydroisoquinoline-7-sulfonamide |
| 05/10/2007 | US20070105833 including cystic fibrosis transmembrane conductance regulator ("CFTR"), such as 4-amido-pyrimidine compounds and derivatives, used for treating genetic disorders; respiratory system disorders |
| 05/10/2007 | US20070105832 e.g. 3-((2-(di-t-butyloxycarbonylamino)pyridin-4-yl)methyl)-4-oxoazetidine-2-carboxylic acid; tryptase, thrombin, trypsin, Factor Xa, Factor VIIa, Factor XIa inhibitor; urokinase-type plasminogen activator; antiallergen; chronic asthma, allergic rhinitis, and thrombotic disorders |
| 05/10/2007 | US20070105831 Carboxamide derivatives as muscarinic receptor antagonists |
| 05/10/2007 | US20070105830 reacting pyrrolidinium-1-[(7-amino-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-yl)methyl]-iodide monohydrate with 4-chloro -2-methoxyimino-3-oxo-butyryl chloride; cyclization |
| 05/10/2007 | US20070105829 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation |
| 05/10/2007 | US20070105828 Novel polymorph form M of mifepristone and process for its preparation |
| 05/10/2007 | US20070105827 Estrogen receptor modulators |
| 05/10/2007 | US20070105826 Novel fusidic acid derivatives |
| 05/10/2007 | US20070105825 Concurrent drugs |
| 05/10/2007 | US20070105824 Methods for treating degenerative diseases/injuries |
| 05/10/2007 | US20070105823 1,2,Di(decynyl-),3-phosphoglycerol; forms a vesicle membrane due to its high intermolecular cohesive force; hard to convert to a solid or into despersion within wide temperatue range;polymerization inhibition; purity; drug delivery; carriers; foods;cosmetics; dyes; detergents; (de)emulsifiers |
| 05/10/2007 | US20070105822 Novel uses of known drugs |
| 05/10/2007 | US20070105821 Acetylation of a 5,6-diamino-1H-pyrimidine-2,4-dione in an aprotic solvent in the presence of a base; selective antagonists of A2B adenosine receptors |
| 05/10/2007 | US20070105820 Oxindole compounds and their uses as therapeutic agents |
| 05/10/2007 | US20070105819 CB-1 modulating compounds and their use |
| 05/10/2007 | US20070105818 Water solubility, bioavailability, oral administration; unit dosage |
| 05/10/2007 | US20070105817 Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension |
| 05/10/2007 | US20070105816 Edulcorant compositions |
| 05/10/2007 | US20070105815 Biocompatible poly-beta-1-4-N-acetylglucosamine |
| 05/10/2007 | US20070105814 for increasing lipopolysaccharide-induced secretion of IL-1 by macrophages, for increasing serum levels of IL-1, and for increasing serum level of IL-1 receptor antagonist |
| 05/10/2007 | US20070105813 Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same |
| 05/10/2007 | US20070105812 Treating HIV-1 viral infections by administering a phospholipid choline derivative, e.g., 1-dodecanamido-2-decyloxypropyl-3-phosphocholine |
| 05/10/2007 | US20070105811 Treating hepatitis B viral infections by administering a phospholipid choline derivative, e.g., 1-dodecanamido-2-decyloxypropyl-3-phosphocholine |
| 05/10/2007 | US20070105810 Therapeutics |
| 05/10/2007 | US20070105801 Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| 05/10/2007 | US20070105797 Antisense inhibition of laminin-8 expression to inhibit human gliomas |
| 05/10/2007 | US20070105793 Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease |
| 05/10/2007 | US20070105792 Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases |
| 05/10/2007 | US20070105791 broad spectrum antibiotic activity; Gram-positive bacteria such as Clostridium, Staphylococcus, Enterococcus species; comprises tiacumicin B, lipiarmycin A4, and at least one of other macrocyclic compounds |
| 05/10/2007 | US20070105790 Pancreatic cancer treatment using Na+/K+ ATPase inhibitors |
| 05/10/2007 | US20070105789 Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors |
| 05/10/2007 | US20070105787 Use of ribose in recovery from anaesthesia |